LETTER TO JMG

Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells

Hafid Alazzouzi¹, Gianpaolo Suriano², Angel Guerra¹, Alberto Plaja¹, Eloi Espín¹, Manel Armengol¹, Pia Alhopuro³, Sergia Velho³, Yasuhisa Shinomura⁴, Juan José González-Aguilera⁵, Hiroyuki Yamamoto⁴, Lauri A Aaltonen³, Víctor Moreno⁶, Gabriel Capellà⁷, Miguel Angel Peinado⁸, Raquel Seruca², Diego Arango¹, Simó Schwartz, Jr¹

¹ Molecular Oncology and Aging Research, Centre d’Investigacions en Bioquímica i Biologia Molecular (CIBBIM), Institut de Recerca Hospital Universitari Vall d’Hebron, Barcelona, Spain
² Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Porto, Portugal
³ Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
⁴ First Department of Internal Medicine, Sapporo Medical University, Chuo-ku, Sapporo, Japan
⁵ Unidad de Genética, Departamento de Biología, Universidad Autónoma de Madrid, Madrid, Spain
⁶ Cancer Epidemiology Service, Institut Català d’Oncologia, L’Hospitalet, Barcelona, Spain
⁷ Translational Research Unit, Institut Català d’Oncologia, L’Hospitalet, Barcelona, Spain
⁸ IDIBELL-Institut de Recerca Oncològica, Barcelona, Spain

Correspondence to:
Dr S Schwartz Jr
Molecular Oncology and Aging Group, Centre d’Investigacions en Bioquímica i Biologia Molecular (CIBBIM), Institut de Recerca Hospital Universitari Vall d’Hebron, Passeig Vall d’Hebron 119–129, Barcelona 08035, Spain;sschwartz{at}ir.vhebron.net

Background: Mdm2 is a natural inhibitor of p53 function and its overexpression impairs p53 transcriptional activity. TG single-nucleotide polymorphism at position 309 (SNP309) of mdm2 induces overexpression of mdm2, but inhibits p53.

Objectives: To determine whether SNP309 is a risk-modifier polymorphism in colorectal cancer (CRC) and whether tumour selection of P53 mutations are influenced by SNP309.

Methods: Single-stranded conformation polymorphism and automatic sequencing were performed.

Results: SNP309 is not associated with the risk of CRC or recurrence of tumours. These data do not over-ride the tumour-selection capabilities of P53 mutations in CRC. However, a significant association with non-dominant-negative P53 mutations (p = 0.02) was found.

Conclusions: MDM2-SNP309 favours tumour selection of non-dominant negative P53 mutations in CRC, which also show an earlier age of tumour onset.

Abbreviations: CRC, colorectal cancer; LOH, loss of heterozygosity; PCR, polymerase chain reaction; SNP309, single-nucleotide polymorphism at position 309; SSCP, single-stranded conformation polymorphism

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Firoz, E. F., Warycha, M., Zakrzewski, J., Pollens, D., Wang, G., Shapiro, R., Berman, R., Pavlick, A., Manga, P., Ostrer, H., Celebi, J. T., Kamino, H., Darvishian, F., Rolnitzky, L., Goldberg, J. D., Osman, I., Polsky, D. (2009). Association of MDM2 SNP309, Age of Onset, and Gender in Cutaneous Melanoma. Clin. Cancer Res. 15: 2573-2580 [Abstract] [Full Text]  
• Hu, Z., Jin, G., Wang, L., Chen, F., Wang, X., Shen, H. (2007). MDM2 Promoter Polymorphism SNP309 Contributes to Tumor Susceptibility: Evidence from 21 Case-Control Studies. Cancer Epidemiol. Biomarkers Prev. 16: 2717-2723 [Abstract] [Full Text]  
• Wilkening, S., Bermejo, J. L., Hemminki, K. (2007). MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 28: 2262-2267 [Abstract] [Full Text]  
• Sanchez-Carbayo, M., Socci, N. D., Kirchoff, T., Erill, N., Offit, K., Bochner, B. H., Cordon-Cardo, C. (2007). A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer. Clin. Cancer Res. 13: 3215-3220 [Abstract] [Full Text]